Selank

Overview

Selank is a synthetic heptapeptide (7-amino acid peptide) with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is derived from tuftsin, a naturally occurring immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg), with the addition of a Pro-Gly-Pro tripeptide extension designed to enhance enzymatic stability and plasma half-life. The compound was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, the same research institution that developed Semax and other research peptides studied extensively in Russia.

Selank was approved in Russia in 2009 as an anxiolytic medication administered via intranasal spray, positioned as an anti-anxiety agent that does not produce sedation-a key distinction from traditional benzodiazepines. The mechanism of action involves modulation of GABA, serotonin, dopamine, and norepinephrine neurotransmitter systems, in addition to immunomodulatory properties inherited from its tuftsin base structure. This multi-system activity distinguishes Selank from typical anxiolytics, as it combines anxiolytic effects with cognitive enhancement and immune modulation in a single molecule.

Selank remains unapproved by the FDA and has not undergone clinical trials in the United States. All published human clinical data derives from Russian clinical trials and post-marketing surveillance in Russia. The peptide is available in some international research contexts but is not commercially available in the United States outside of personal import from countries where it is approved.

FDA and Regulatory Status

As of April 2026:

• NOT FDA-approved for any indication in the United States
• Approved in Russia (2009) as an intranasal anxiolytic for generalized anxiety disorder and anxiety-related conditions
• No IND application or clinical trials in U.S.. No FDA development program exists
• Limited availability outside Russia: Some availability in Eastern European and Commonwealth of Independent States (CIS) countries
• Not approved in Europe (EMA), UK, Canada, Australia, or other major regulatory jurisdictions

The Russian approval of Selank represents the regulatory decision-making of a single major jurisdiction. Approval in Russia does not necessarily predict FDA approval pathway or success in Western clinical development, though the existence of clinical data is valuable for research purposes.

Mechanism of Action

Selank's mechanisms involve modulation of multiple neurotransmitter and immunological systems, distinguishing it from traditional single-target anxiolytics:

1. GABA System Modulation

A primary mechanism of Selank's anxiolytic effects is modulation of GABAergic signaling, the primary inhibitory neurotransmitter system in the brain. In contrast to benzodiazepines, which directly enhance GABA-A receptor function, Selank is believed to increase GABA availability or enhance GABA synthesis and release. Published Russian research has documented increases in GABA levels in brain tissue following Selank administration and has suggested mechanisms involving enhanced glutamic acid decarboxylase (GAD) activity, the enzyme responsible for GABA synthesis. This GABA-modulatory mechanism contributes to anxiolytic effects without the direct receptor agonism that characterizes benzodiazepines.

2. Serotonin and Monoamine System Effects

Clinical and preclinical studies have reported that Selank affects serotonin (5-HT) neurotransmission, with evidence suggesting increased serotonin availability in the brain. Additionally, Selank appears to modulate dopamine and norepinephrine systems, as documented by studies measuring neurotransmitter levels and receptor expression in animal models. These effects may contribute to Selank's anxiolytic properties (via serotonin) while also supporting cognitive function and mood stabilization (via dopamine and norepinephrine). This multi-monoamine activity distinguishes Selank from SSRIs and traditional anxiolytics that typically focus on single neurotransmitter systems.

3. Brain-Derived Neurotrophic Factor (BDNF) Enhancement

Russian research has documented that Selank enhances expression of brain-derived neurotrophic factor (BDNF) in animal models and in human patient samples. BDNF is a critical growth factor for neuroplasticity, learning, memory formation, and mood regulation. Enhanced BDNF expression may contribute to long-term anxiolytic effects and cognitive enhancement by supporting neuronal survival, growth, and synaptic plasticity. This mechanism may explain why Selank has been studied for cognitive applications alongside its anxiolytic properties.

4. Immunomodulatory Effects via Tuftsin Component

The tuftsin-derived core of Selank (Thr-Lys-Pro-Arg) contributes immunomodulatory properties. Tuftsin is an endogenous tetrapeptide released from IgG that enhances phagocytic activity of macrophages and neutrophils. Selank retains this immunomodulatory activity, and studies have documented enhanced immune cell function (macrophage and neutrophil activation) following Selank administration. This immunomodulatory component is unusual for an anxiolytic, as most traditional anti-anxiety agents do not affect immune function.

5. Neuroprotective and Anti-Inflammatory Effects

Preclinical studies have suggested that Selank may have neuroprotective properties against various forms of neuronal injury and may reduce neuroinflammation. These effects appear mediated through a combination of BDNF enhancement, antioxidant activity, and modulation of pro-inflammatory cytokine production. The mechanism may involve suppression of NF-κB signaling or other anti-inflammatory pathways, though the specific mechanisms have not been fully characterized in human studies.

6. Stress Adaptation and HPA Axis Modulation

Some Russian research has suggested that Selank may enhance stress adaptation and modify hypothalamic-pituitary-adrenal (HPA) axis function, though this remains incompletely characterized. The peptide may help normalize cortisol responses to stress or enhance recovery from stress-induced HPA activation, potentially contributing to its anxiolytic and mood-enhancing properties.

Common Research Applications

Generalized Anxiety Disorder (GAD)

Generalized anxiety disorder is the primary approved indication for Selank in Russia, with the peptide approved specifically for treatment of GAD in Russian clinical practice. Clinical trials conducted in Russia have examined Selank as intranasal spray versus placebo in patients with GAD, with studies reporting reductions in anxiety symptoms as measured by standard anxiety scales (State-Trait Anxiety Inventory, Hamilton Anxiety Rating Scale). The advantage claimed for Selank over traditional benzodiazepines is anxiolytic effect without sedation, which may be particularly valuable for patients who require anxiety reduction while maintaining alertness for work or other activities.

Cognitive Enhancement and Memory Support

Selank has been studied in Russian research contexts for potential cognitive enhancement and memory improvement, based on BDNF enhancement mechanisms and multi-monoamine activity. While the primary approved indication is anxiety, clinical research has examined Selank's effects on cognitive function, verbal learning, and memory in various populations. The rationale is that BDNF enhancement and neuroplasticity support underlie cognitive benefits, making Selank potentially useful for students, aging populations, or those with cognitive decline.

Stress-Related Conditions and Adaptation

Given Selank's stress-adaptation mechanisms and HPA axis effects, the peptide has been studied in populations exposed to high stress (military personnel, high-stress occupations, severe life stress). The mechanism involves enhancing resilience to stress and supporting recovery from acute stress exposure. Russian research has examined Selank in occupational stress contexts and chronic stress situations.

Immunocompromised States and Immune Support

The immunomodulatory properties derived from tuftsin have prompted investigation of Selank in immunocompromised populations or during immune challenges. Research has examined Selank in patients with chronic infections, during viral illness, or in populations requiring immune support. The mechanism involves enhanced macrophage and neutrophil activation through the tuftsin-derived component.

Depression and Mood Disorders

Some research contexts have examined Selank for depressive symptoms and mood enhancement, based on monoamine system effects and BDNF enhancement. While anxiety is the primary clinical focus, the neurobiological mechanisms (serotonin, dopamine, BDNF) are relevant to depression pathophysiology, prompting investigation in mood disorders.

Neuroprotection and Neurodegenerative Disease

Based on neuroprotective mechanisms and BDNF-enhancement, Selank has been investigated in preclinical and early clinical research contexts for potential neuroprotective effects against various forms of neuronal injury or neurodegenerative processes. This remains an exploratory application with limited clinical evidence.

Studied Benefits and Clinical Evidence

Important caveat: Published clinical evidence for Selank derives primarily from Russian clinical trials and research. The quality and extent of this evidence is generally more substantial than preclinical-only compounds but less extensive than Western pharmaceutical development typically generates. All clinical evidence is from Russian sources; there are no published U.S. clinical trials.

Anxiolytic Effects Without Sedation

The core clinical evidence for Selank comes from clinical trials demonstrating anxiolytic effects in GAD patients. Russian clinical trials employing standardized anxiety rating scales (HAM-A, STAI) have documented that Selank intranasal spray reduces anxiety symptoms. A key reported distinction from benzodiazepines is that Selank produces anxiolytic effects without sedation. This is supported by reports that patients receiving Selank maintain alertness and do not experience the drowsiness associated with benzodiazepines. The mechanism proposed is that enhanced GABA availability (rather than direct GABA-A agonism) produces anxiety reduction without sedation. Published trials typically employed doses of 250-500 mcg intranasal daily, with treatment duration of 2-4 weeks showing symptom improvement.

Cognitive Function and Memory Enhancement

Multiple Russian studies have reported cognitive benefits from Selank administration, including improvements in verbal learning, memory retention, and information processing speed, particularly when administered to students or cognitively intact adults without baseline cognitive impairment. These effects are attributed to BDNF enhancement and neuroplasticity support. The studies typically employed neuropsychological testing batteries and documented improvements in specific cognitive domains. However, studies examining Selank in populations with established cognitive impairment (Alzheimer's disease, mild cognitive impairment) are more limited and results less robust.

Stress Resilience and Adaptation

Research in occupational stress contexts (military personnel, high-stress professions, emergency responders) has reported that Selank administration may enhance stress resilience and support faster recovery from acute stress exposure. Studies have documented improvements in stress-related symptoms and better overall function during high-stress situations in Selank-treated groups compared to controls. These effects are attributed to HPA axis modulation and enhanced stress adaptation mechanisms.

Immunological Markers

Clinical and preclinical research has documented immunological changes following Selank administration, including increased macrophage and neutrophil activation markers, enhanced phagocytic activity, and cytokine changes consistent with immune enhancement. These immunological effects support the immunomodulatory mechanism derived from tuftsin. However, clinical significance of these immunological changes in disease prevention or treatment outcomes remains incompletely characterized.

Safety and Tolerability

Russian clinical data reports that Selank is well-tolerated with minimal adverse effects across the clinical trial population. The reported safety profile has supported its regulatory approval in Russia and continues use in Russian clinical practice. Adverse events reported in trials are minimal, with the most common being occasional mild nasal irritation (intranasal administration) or occasional mild headache. Serious adverse events have not been documented in published Russian trials.

Dosing and Administration

Standard Clinical Dosing

Intranasal (Approved Route): The standard clinical dose in Russian approved use is 250-500 mcg intranasal daily, typically administered as a nasal spray. Some protocols employ 250 mcg once daily in morning, while others use 250-500 mcg once or twice daily depending on symptom severity and individual response. Treatment duration in clinical trials typically ranged from 2-4 weeks, though some protocols extended to 8-12 weeks for chronic anxiety management.

Subcutaneous (Research Contexts): In research contexts and in some clinical settings outside the approved intranasal formulation, Selank has been administered subcutaneously at doses ranging from 100-300 mcg per dose, typically given once or twice daily. These doses represent extrapolations from intranasal dosing and the assumption of lower bioavailability from subcutaneous administration.

Bioavailability and Absorption

Intranasal administration allows direct delivery to the central nervous system via olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier and potentially achieving higher brain concentrations than systemic administration would produce. This intranasal route is the clinically approved route in Russia and is believed to optimize CNS delivery. Intranasal bioavailability in humans has not been formally characterized in published studies, though the route is presumed to provide efficient CNS penetration based on the clinical effects observed.

Pharmacokinetics

Published pharmacokinetic data in humans is limited. Preclinical studies suggest that Selank has a relatively short plasma half-life, estimated at 30-40 minutes based on animal studies, though human PK data is not available in published literature. The short plasma half-life contrasts with the apparent longer duration of pharmacodynamic effects, suggesting that Selank's effects on GABA, BDNF, and other systems may persist after the peptide has been cleared from circulation. This may explain why once-daily dosing appears sufficient despite the apparent short half-life.

Dose Titration and Individual Variation

Clinical practice in Russia employs flexible dosing based on individual response, with lower doses (250 mcg) used for mild anxiety and higher doses (500 mcg) for more severe symptoms. Some protocols involve gradual dose escalation over days to weeks to optimize individual response. No formal dose-response studies have been published, making evidence-based dose optimization limited.

Side Effects and Safety Profile

Notable Safety Advantages

No dependence or withdrawal: Unlike benzodiazepines, Selank does not produce physical dependence or withdrawal effects. Abrupt discontinuation has not been associated with rebound anxiety.

No abuse potential: Selank does not produce euphoria or reward effects and has no documented abuse liability.

No cognitive impairment: Unlike benzodiazepines, Selank does not produce sedation, dizziness, or memory impairment at studied doses.

Long-Term Safety

Most clinical trials have durations of 2–12 weeks. Long-term effects on the immune system, neuroendocrine function, and potential tolerance development are not fully characterized.

Selank vs. Semax: Key Differences

Selank and Semax are both synthetic peptides developed at the same Russian research institution (Institute of Molecular Genetics, Russian Academy of Sciences) and are both approved in Russia but not in Western jurisdictions. However, they represent fundamentally different therapeutic approaches:

Primary Mechanisms

Selank: GABA and serotonin modulation with anxiolytic primary effect, combined with BDNF enhancement and immunomodulation from tuftsin component.

Semax: BDNF and NGF upregulation with neuroprotective and nootropic primary effects; does not target GABA or serotonin systems.

Clinical Indication

Selank: Approved for anxiety (generalized anxiety disorder),a condition affecting mood and emotional regulation.

Semax: Approved for neurological indications (stroke recovery, cognitive disorders),conditions affecting brain function and structure.

Pharmacological Approach

Selank: "Calming/anxiolytic",reduces anxiety and may impair alertness, though claims of no sedation in research literature.

Semax: "Activating/cognitive enhancing",promotes cognitive function and mental clarity without anxiolytic properties.

Immunomodulation

Selank: Contains tuftsin component providing immunomodulatory (macrophage/neutrophil activation) effects.

Semax: Not designed for immune effects; no immunomodulatory component.

Research Applications

Selank: Primarily for anxiety, depression, stress adaptation, and cognitive enhancement secondary to anxiety reduction.

Semax: Primarily for neuroprotection, stroke recovery, cognitive enhancement, ADHD, and neurotrauma.

Practical Distinction

While both peptides originate from the same research institution and share approval status (approved in Russia, not in West), they address different medical needs. Selank is for patients seeking anxiety reduction, while Semax is for patients seeking cognitive/neurological support without sedation. They are not substitutes but rather complementary peptides with different clinical applications.

Stacking Considerations

In research community discussions, Selank is sometimes described in combination protocols with other anxiolytic-supporting peptides or neuromodulatory agents, based on the theory that complementary mechanisms could enhance anxiety reduction and mood support. The proposed rationale is that Selank's proposed anxiolytic effects (potentially through argipressin-system modulation) could be combined with other neuropeptides supporting mood, stress resilience, or GABA-ergic function. However, no published human studies have examined the safety or efficacy of Selank combined with other peptides or compounds.

Commonly Discussed Research Combinations

Reported protocols in research contexts sometimes describe Selank stacked with agents such as its structural relative Semax (though they have different intended purposes), other neuropeptides, or compounds targeting GABAergic, serotonergic, or other mood-related pathways. Some discussions involve combining Selank with stress-resilience peptides or compounds supporting HPA-axis function. These combinations remain entirely theoretical, based on mechanistic reasoning rather than human clinical evidence. The assumption that different anxiolytic mechanisms will produce additive effects lacks human validation.

Safety Considerations in Combination

Combining multiple neuromodulatory agents introduces theoretical risks: excessive GABA-ergic or other inhibitory signaling, CNS depression, potential mood dysregulation, and unknown pharmacodynamic interactions affecting stress-response systems. Without human safety data for Selank alone or in any combination, the responsible approach emphasizes single-agent clinical research before advancing to combination protocols.

Evidence Status: No published human studies have examined Selank combined with other peptides or neuromodulatory compounds. All reported stacking discussions represent theoretical extrapolations without clinical evidence of safety or efficacy.

Frequently Asked Questions